GO
Loading...

FDA

More

  • GPC Prostate Drug Needs More Data, FDA Panel Says Tuesday, 24 Jul 2007 | 5:13 PM ET

    U.S. regulators should wait for final survival data before deciding whether to approveGPC Biotech proposed prostate cancer pill Orplatna, an advisory panel said on Tuesday in a 12-0 vote.

  • FDA Seeks More Data on Wyeth Menopause Drug Tuesday, 24 Jul 2007 | 10:16 AM ET

    The FDA is seeking a one-year study of how the drug Pristiq affects the heart and liver, said Wyeth's chief medical officer, Dr. Gary Stiles.

  • FDA: Throw Away 90 Botulism-Linked Products Tuesday, 24 Jul 2007 | 4:54 AM ET

    People should immediately throw away more than 90 different products, from chili sauce to corned beef hash to dog food, produced at a plant linked to a botulism outbreak, the government warned Monday.

  • U.S. drug reviewers will ask an advisory panel if they should wait for more data before deciding whether to approve GPC Biotech proposed prostate cancer pill, a summary released Friday said.

  • New Bush Panel to Police Food Imports Wednesday, 18 Jul 2007 | 2:27 PM ET

    President Bush established a high-level government panel to recommend steps to guarantee the safety of food and other products shipped into the United States and to improve U.S. policing of those imports. The White House denied the effort was aimed primarily at China.

  • Philippine authorities tested more Chinese products Wednesday after ordering several candy and cookie brands found to be tainted with an embalming chemical to be withdrawn from stores, the country's food safety watchdog said.

  • Imclone Falls After Erbitux Trial Fail To Meet Endpoint Thursday, 12 Jul 2007 | 10:16 AM ET

    Shares of Imclone Systems fell after the company announced that phase III studies of its cancer drug Erbitux failed to meet the end point of progression free survival of non-small cell lung cancer.

  • The U.S. imports approximately 15% of its food -- and China is its third largest supplier. This week, China admitted it needs to raise food safety standards to international levels, amid the recent controversy of tainted Chinese foods. Chris Waldrop, director of the food and policy institute at the Consumer Federation of America, and Michael Doyle, director of the center for food safety at the University of Georgia, discussed the situation on “Power Lunch.”

  • Imported Seafood from China on Increased FDA Radar Thursday, 5 Jul 2007 | 11:05 AM ET

    A senior scientist at Consumers Union told "Squawk Box" that the U.S. regulators need to step-up inspections of food coming from China, particularly seafood.

  • FDA Detains Shipments of Chinese Seafood Thursday, 28 Jun 2007 | 4:22 PM ET

    Federal health officials said Thursday that they were detaining three types of Chinese fish -- catfish, basa and dace -- as well as shrimp and eel after repeated testing has turned up contamination with drugs unapproved in the United States for use in farmed seafood.

  • Pfizer said after markets closed Wednesday that U.S. health regulators will approve its novel AIDS drug called maraviroc once certain conditions have been met, although the world's biggest drugmaker did not elaborate on what was necessary to obtain an outright approval.

  • Gilead Sciences shares rose in aftermarket trading on Friday after the U.S. Food and Drug Administration approved the drugmaker's treatment for high blood pressure in the lungs.

  • Investors wiped some 6 billion euros ($7.97 billion) off the market value of French pharmaceutical company Sanofi-Aventis Thursday after U.S. federal health advisers rejected its Accomplia weight-loss drug.

  • Glaxo Faces U.S. Investor Lawsuit Over Avandia Tuesday, 12 Jun 2007 | 12:02 PM ET

    GlaxoSmithKline faces a U.S. investor lawsuit claiming that Europe's biggest drugmaker misled shareholders about the safety of diabetes drug Avandia.

  • Turning the tables on the United States amid growing worries over dangerous Chinese products, Beijing said Friday some health supplements and raisins imported from the U.S. failed to meet China's safety standards and have been returned or destroyed.

  • FDA's Post-Market Drug Safety Program Called 'Broken' Wednesday, 6 Jun 2007 | 12:23 PM ET

    Paul Brown, consumer healthcare advocate at the U.S. Public Interest Research Group, told CNBC’s “Morning Call” that the Food and Drug Administration’s post-market safety program is “broken.”

  • U.S. FDA Chief Says Avandia Data Still Inconsistent Wednesday, 6 Jun 2007 | 11:30 AM ET

    All studies to date provide inconsistent data about the potential contribution of GlaxoSmithKline's diabetes drug Avandia to heart attack risk, the head of the Food and Drug Administration said in testimony prepared for a congressional hearing on Wednesday.

  • In an exclusive interview on CNBC, GlaxoSmithKline’s CEO J.P. Garnier defended the company's diabetes drug Avandia, saying recent safety questions are based on statistical analysis, not medical evidence.

  • Dendreon: the Ride Thursday, 31 May 2007 | 10:42 AM ET

    Before the bell this morning, the ever-popular Dendreon put out a press release ahead of its presentation later today at the Bank of America Healthcare Conference in Las Vegas. You can listen to the presentation via Webcast at 1 p.m. ET. The company says that the Food and Drug Administration has confirmed that it will "accept either a positive interim or final analysis of survival" from the ongoing, larger clinical trial on Dendreon's highly controversial prostate cancer treatment Provenge.

  • Wyeth Wins FDA Approval for Kidney Cancer Drug Wednesday, 30 May 2007 | 4:56 PM ET

    Wyeth's drug Torisel won U.S. approval to treat patients with a type of advanced kidney cancer known as renal cell carcinoma, the Food and Drug Administration said.